Landscape Capital Management L.L.C. Raises Position in Glaukos Corporation $GKOS

Landscape Capital Management L.L.C. grew its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 125.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 23,017 shares of the medical instruments supplier’s stock after purchasing an additional 12,799 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Glaukos were worth $2,599,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AustralianSuper Pty Ltd lifted its holdings in shares of Glaukos by 10.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after purchasing an additional 43,750 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after purchasing an additional 27,646 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Glaukos by 460.8% during the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after purchasing an additional 49,492 shares during the last quarter. TD Asset Management Inc purchased a new position in Glaukos in the 3rd quarter worth $1,157,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Glaukos by 32.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after acquiring an additional 87,781 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leana Wen sold 1,700 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director owned 19,739 shares in the company, valued at $2,829,585.65. This trade represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,930 shares of company stock valued at $6,321,363 over the last quarter. Insiders own 5.90% of the company’s stock.

Glaukos Price Performance

NYSE:GKOS opened at $126.76 on Monday. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $148.11. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $7.44 billion, a PE ratio of -38.65 and a beta of 0.83. The stock’s 50-day moving average price is $124.00 and its 200-day moving average price is $116.31.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. During the same period last year, the firm earned ($0.22) EPS. The company’s quarterly revenue was up 41.2% on a year-over-year basis. As a group, equities analysts expect that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Stifel Nicolaus set a $170.00 target price on Glaukos in a research note on Thursday, April 30th. William Blair restated an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. JPMorgan Chase & Co. raised their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. BTIG Research restated a “buy” rating and issued a $162.00 target price on shares of Glaukos in a research note on Wednesday, June 10th. Finally, Needham & Company LLC raised their target price on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $148.00.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.